Manchester Academic Health Science Centre Technology Hub: Clinical Proteomics Centre for Stratified Medicine
Lead Research Organisation:
University of Manchester
Department Name: Medical and Human Sciences
Abstract
The genomic and post-genomic age promises much for clinical medicine, as we can now sequence genomes (the blueprint), and measure gene expression fairly routinely and now we can measure the amounts of proteins (the structural and catalytic functional entities in the cell) produced. Yet, to date, the biomedical community have struggled to integrate these technologies and generate the impact anticipated some years ago. The University of Manchester proposes to engage with this challenge by setting up a completely new facility, building on its strengths in biochemistry, to enable clinicians to choose the right treatment for the right patient at the right time. The biochemistry base that will be built, using state of the art technologies, can serve this objective in a number of different ways for a wide range of different diseases. Furthermore, the benefits generated from the facility will be available to researchers from other universities and industrial partners (such as drug companies) to use, with the aim to maximise its impact in diagnostic and translational medicine beyond Manchester.
This new facility will use a new development of mass spectrometry that supports the measurement of many proteins within a sample (such as blood, urine, or from tissue such as a tumour biopsy) within a much shorter time than has ever been possible before. Such techniques will be of huge benefit to clinical researchers as it will allow them to see the differences between samples from, for example, healthy people and people with a specific disease - this will give insights into how that disease develops and, importantly, how it might be treated. In addition, by examining the differences in the levels of particular marker proteins from patients who respond to a drug compared to those who don't respond, doctors will be able to identify which drug is the best treatment for individual patients. This will have economic benefit as drugs will not be used on patients who will receive no benefit from them. We will look in the first instance for such protein markers through the disease course, and treatment response in rheumatoid arthritis, psoriasis and cancer.
This new facility will use a new development of mass spectrometry that supports the measurement of many proteins within a sample (such as blood, urine, or from tissue such as a tumour biopsy) within a much shorter time than has ever been possible before. Such techniques will be of huge benefit to clinical researchers as it will allow them to see the differences between samples from, for example, healthy people and people with a specific disease - this will give insights into how that disease develops and, importantly, how it might be treated. In addition, by examining the differences in the levels of particular marker proteins from patients who respond to a drug compared to those who don't respond, doctors will be able to identify which drug is the best treatment for individual patients. This will have economic benefit as drugs will not be used on patients who will receive no benefit from them. We will look in the first instance for such protein markers through the disease course, and treatment response in rheumatoid arthritis, psoriasis and cancer.
Technical Summary
This bid proposes the development of a unique world-leading clinical proteomics centre (CPC) for stratified medicine and mechanistic studies of disease. The objectives for the proposed centre include the pragmatic discovery of novel protein biomarkers to lead to early diagnosis of disease, stratification of patients according to their disease endotype and also according to their therapeutic response to a specific treatment. Additionally, we anticipate the CPC will offer a valuable resource for experimental medicine studies to understand the basis of disease mechanisms. Within the proposed CPC we will apply the very latest in innovative mass spectrometry-based technology on a high capacity throughput, for the first time in the UK. Sequential Window Acquisition of all THeoretical fragment-ion spectra Mass Spectrometry (SWATH MS), combined with Selected Reaction Monitoring (SRM) proteomics techniques will allow the creation of a digitised, quantitative, permanent record of the proteome. Linkage of proteomic data to electronic health records through the Farr@HeRC health informatics centre will be achieved through a secure 'eLab' platform, allowing the integration of complex molecular phenotyping with endotypic data (such as therapeutic outcome and medical history). Exemplar stratified medicine projects will be enabled once CPC is set up, and will include the use of samples from the MRC-funded stratified medicine programmes around psoriasis (PSORT) and rheumatoid arthritis (MATURA), where the digitised proteome can be interrogated alongside other 'omics and clinical data. Additionally, a number of other mechanistic studies around leukaemia and other solid cancers have already been identified and will proceed when the CPC is established. Combined with validation and verification platforms, the facility will offer unparalleled power to discover novel biomarkers and elucidate the underlying pathophysiological mechanisms of disease.
Planned Impact
1) Who will benefit from this research?
- Clinical scientists and experimental medicine researchers
- Clinicians, NHS
- Patients
- Drug discovery/ development groups
- Industry, including big pharma and biotech
2) How will the above groups benefit?
In short, the groups listed above will benefit from a quicker time to clinical validation of biomarkers and the improved prospect of personalised medicine penetration into the clinic with associated economic benefit.
Specifically-
- Clinical scientists and experimental medicine researchers will benefit through being able to access an innovative high capacity resource not currently available elsewhere in the UK, allowing them to undertake discovery biomarker projects and experimental studies in a fraction of the time. The ability to create a permanent digitised record (and subsequently iteratively mine this) will allow precious clinical samples and biobanks to be used sparingly;
- Clinicians and the NHS will benefit through the ultimate development of improved diagnostics and predictors of response, allowing earlier diagnosis and reduction in prescribing errors - all of which will ultimately reduce the necessity of inappropriate or aggressive treatment and, in turn, the economic burden of disease on the health service;
- Patients will benefit through better diagnostics and 'theranostics' by being detected earlier (improving outcome) and, following diagnosis, by being treated right first time;
- Drug discovery and development groups will be able to identify those individuals who are most likely to benefit from the drugs they are developing and allowing them to be targeted appropriately (reducing side effects and non-response);
- Pharma will benefit by being able to access a facility which will allow them to identify novel "druggable" targets through the comparison of proteomic signatures from patients and healthy volunteers, mass spectrometry instrument manufacturers (and specifically AB SCIEX and Waters) will benefit through having their techniques validated and translated into clinical practice (and the potentially larger market share this will bring), smaller biotech will benefit from pharma's increased use of protein or expression based diagnostics and the opportunities this will bring in terms of companion diagnostic development
- Clinical scientists and experimental medicine researchers
- Clinicians, NHS
- Patients
- Drug discovery/ development groups
- Industry, including big pharma and biotech
2) How will the above groups benefit?
In short, the groups listed above will benefit from a quicker time to clinical validation of biomarkers and the improved prospect of personalised medicine penetration into the clinic with associated economic benefit.
Specifically-
- Clinical scientists and experimental medicine researchers will benefit through being able to access an innovative high capacity resource not currently available elsewhere in the UK, allowing them to undertake discovery biomarker projects and experimental studies in a fraction of the time. The ability to create a permanent digitised record (and subsequently iteratively mine this) will allow precious clinical samples and biobanks to be used sparingly;
- Clinicians and the NHS will benefit through the ultimate development of improved diagnostics and predictors of response, allowing earlier diagnosis and reduction in prescribing errors - all of which will ultimately reduce the necessity of inappropriate or aggressive treatment and, in turn, the economic burden of disease on the health service;
- Patients will benefit through better diagnostics and 'theranostics' by being detected earlier (improving outcome) and, following diagnosis, by being treated right first time;
- Drug discovery and development groups will be able to identify those individuals who are most likely to benefit from the drugs they are developing and allowing them to be targeted appropriately (reducing side effects and non-response);
- Pharma will benefit by being able to access a facility which will allow them to identify novel "druggable" targets through the comparison of proteomic signatures from patients and healthy volunteers, mass spectrometry instrument manufacturers (and specifically AB SCIEX and Waters) will benefit through having their techniques validated and translated into clinical practice (and the potentially larger market share this will bring), smaller biotech will benefit from pharma's increased use of protein or expression based diagnostics and the opportunities this will bring in terms of companion diagnostic development
Organisations
- University of Manchester (Collaboration, Lead Research Organisation)
- Korea University (Collaboration)
- ETH Zurich (Collaboration)
- Inoviv (Collaboration)
- Macquarie University (Collaboration)
- Cardiff University (Collaboration)
- Shanghai Institute of Materia Medica, China (Collaboration)
- Korea Institute of Science and Technology Information (KISTI) (Collaboration)
- AB SCIEX (Collaboration)
- Fudan University (Collaboration)
- University of Cape Town (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- University of Bristol (Collaboration)
- University College London (Collaboration)
- The Garvan Institute for Medical Research (Collaboration)
- Chang Gung University (Collaboration)
- National Cancer Centre (Collaboration)
- University of Dundee (Collaboration)
- Academia Sinica (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- McGill University (Collaboration)
- Chinese Academy of Sciences (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Leibniz Association (Collaboration)
- Lund University (Collaboration)
- Sheffield Teaching Hospitals NHS Foundation Trust (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- Kinomica (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications
Geary B
(2019)
Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients.
in Journal of proteome research
Geifman N
(2020)
A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases.
in Journal of translational medicine
Gibb A
(2021)
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
in British journal of haematology
Harrison OJ
(2018)
Candidate plasma biomarkers for predicting ascending aortic aneurysm in bicuspid aortic valve disease.
in Journal of cardiothoracic surgery
Heald A
(2020)
Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis.
in Clinical proteomics
Iqbal Z
(2021)
The Effect of Bariatric Surgery on the proteome of people achieving remission of Type 2 Diabetes
in Endocrine Abstracts
Ismail N
(2020)
Vitamin B5 (d-pantothenic acid) localizes in myelinated structures of the rat brain: Potential role for cerebral vitamin B5 stores in local myelin homeostasis.
in Biochemical and biophysical research communications
Larkin SE
(2016)
Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
in British journal of cancer
Littler S
(2019)
Oncogenic MYC amplifies mitotic perturbations.
in Open biology
| Description | MRC Workshop on Methodology for Stratified Medicine - July 2015. 'Stratum Verification' |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Rosalind Franklin Institute Biological Mass Spectrometry |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | UK Biobank Enhancement Working Group |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Biomarker Discovery and Validation in Prostate Cancer |
| Amount | £40,000 (GBP) |
| Organisation | Male Uprising Guernsey |
| Sector | Charity/Non Profit |
| Country | Guernsey |
| Start | |
| End | 12/2020 |
| Description | Biomedical Research Centre |
| Amount | £28,500,000 (GBP) |
| Organisation | University of Leicester |
| Department | NIHR Biomedical Research Centre |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2021 |
| Description | Earlier Detection of NSCLC relapse after Surgery with Liquid Biopsies and Frequent Community Based Blood Collection |
| Amount | £631,724 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Eradication of the Leukaemic clone in myeloproliferative neoplasms |
| Amount | £297,000 (GBP) |
| Funding ID | 19007 |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | MICA: NURTuRE - changing the landscape of renal medicine to foster a unified approach to stratified medicine |
| Amount | £2,561,603 (GBP) |
| Funding ID | MR/R013942/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 07/2022 |
| Description | Manchester ECMC |
| Amount | £280,900 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 08/2017 |
| Description | Manchester Molecular Pathology Innovation Centre (MMPathIC): bridging the gap between biomarker discovery and health and wealth |
| Amount | £2,923,765 (GBP) |
| Funding ID | MR/N00583X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 03/2020 |
| Description | Manchester/MCRC Early Recognition of Cancer And Decision Options (MERCADO) |
| Amount | £3,200,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Molecular Pathology Nodes Call Feb 2015 |
| Amount | £2,886,686 (GBP) |
| Funding ID | MR/N00583X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | NIHR Biomedical Research Centre: Cancer Prevention and Early Detection Theme |
| Amount | £635,894 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | NURTuRE- changing the landscape of renal medicine to foster a unified approach to stratified medicine |
| Amount | £3,100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Research Grant |
| Amount | £604,167 (GBP) |
| Funding ID | MR/N028457/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2020 |
| Description | Research Grant |
| Amount | £324,224 (GBP) |
| Funding ID | BB/P024424/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2020 |
| Description | Small pilot grants |
| Amount | £15,000 (GBP) |
| Organisation | Genesis Breast Cancer Prevention Appeal |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 10/2016 |
| Description | Wellcome Trust Institute Strategic Support Fund (University of Manchester) |
| Amount | £44,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 09/2016 |
| Description | Assessment of DDA methods on Thermo and SCIEX LC/MS systems using phosphoproteomics |
| Organisation | Kinomica |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | DDA |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Biomarker discovery for acute myeloid leukaemia using a proteomic approach_1 |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2016 |
| Description | CLUSTER |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Determining the role of deubiquitinases in chronic lymphocytic leukaemia pathogenesis |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | iTRAQ MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Developing a biomarker to predict risk of aortopathy in patients with bicuspid aortic valve disease |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supplied samples |
| Impact | N/A |
| Start Year | 2016 |
| Description | Discovery work with Inoviv on CSF |
| Organisation | Inoviv |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | DDA, SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Evaluation of key Biomarkers for the prediction of successful treatment-free remission (TFR) in chronic myeloid leukaemia |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Grey Platelet Syndrome Study |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2018 |
| Description | INTERVAL BioResource |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Identifying transcription factors that mediate the developmental disruption caused by RUNX1-ETO |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Academia Sinica |
| Country | Taiwan, Province of China |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Chang Gung University |
| Country | Taiwan, Province of China |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Chinese Academy of Sciences |
| Country | China |
| Sector | Public |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | ETH Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Fudan University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Korea Institute of Science and Technology Information (KISTI) |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Korea University |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Leibniz Association |
| Department | Leibniz Institute for Analytical Sciences |
| Country | Germany |
| Sector | Charity/Non Profit |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Macquarie University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | McGill University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | National Cancer Centre |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | National Institutes of Health (NIH) |
| Department | National Cancer Institute (NCI) |
| Country | United States |
| Sector | Public |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | Shanghai Institute of Materia Medica, China |
| Country | China |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | The Garvan Institute for Medical Research |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | International Cancer Proteogenome Consortium- Cancer Moonshot |
| Organisation | University of Dundee |
| Department | School of Life Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Collaborator Contribution | International proteomics network for cancer research that is sharing best practice sample processing and mass spectrometry protocols and data from various tumour samples. |
| Impact | Proteomics collaboration, outputs so far include standard operating procedures agreed by consortium. |
| Start Year | 2017 |
| Description | OPTIMISE FP7 |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2018 |
| Description | Predicting response to clozapine in treatment resistant schizophrenia |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Progressive/regressive airway CIS |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2018 |
| Description | Proteomic profile in active lupus nephritis patients and renal biopsy samples |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2018 |
| Description | Rheumatic Heart Disease |
| Organisation | University of Cape Town |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | Stoller/SCIEX research collaboration |
| Organisation | AB SCIEX |
| Country | United States |
| Sector | Private |
| PI Contribution | Stoller staff are providing intellectual input, access to facilities and equipment and will be training PhD students. The goal of the partnership is to industrialise proteomics with appropriate QA/QC measures. |
| Collaborator Contribution | SCIEX staff are providing on site support from field service engineers to maintain the equipment and application chemists advising on use of the instrumentation, training new users and jointly developing new methodologies. The goal of the partnership is to industrialise proteomics with appropriate QA/QC measures. |
| Impact | Joint poster presentations at ASMS and HUPO conferences. Sponsored seminars at various international conferences. VIP round table discussions on the advancement of precision medicine and the major challenges researchers face. |
| Start Year | 2016 |
| Description | Strat Med CKD project, NURTuRE |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | TASTER-Targeting STEm cell resistance |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DDA, SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | The acute effects of Remote Ischaemic Conditioning (RIC) on cerebral perfusion |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2019 |
| Description | The role of the transcription factor SOX9 in liver fibrosis |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DDA, SWATH-MS |
| Collaborator Contribution | Supply of samples |
| Impact | N/A |
| Start Year | 2016 |
| Description | BRC Scientific Advisory Board |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Multiple discussions including seminars, strategic discussion on the BRC and discussions about the latest information on pipelines, cancer, hearing and inflammation. |
| Year(s) Of Engagement Activity | 2020 |
| Description | CRUK-Abcodia Science Advisory Board |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | I was invited to become a member of the Science Advisory Board for collaboration between Cancer Research UK and Abcodia, the biomarker validation company. The main reason for this collaboration is to develop new tests to detect various cancers before patients develop any symptoms. |
| Year(s) Of Engagement Activity | 2013,2014,2015,2016,2017,2018,2019 |
| Description | Cub scouts visit to the Stoller |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | 48 cub scouts aged 8-11 years old attended an evening visit to the Stoller Biomarker Discovery Centre where staff engaged in fun experiments designed to interest children in science. The feedback from the visitors has been very positive with additional visits from older scout troops planned for later in the year. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Interview for Front Line Genomics |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interviewed by the Editor of Front Line Genomics about the talk presented the the UK Biobank Annual Conference entitled "Strategy for large-scale multi-omics in UK Biobank" |
| Year(s) Of Engagement Activity | 2019 |
| Description | MRC group on Stratification in next 30 years |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | MRC group on Stratification in next 30 years |
| Year(s) Of Engagement Activity | 2019 |
| Description | NIHR BRC Workshop on Oncology Initiatives |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | NIHR BRC Workshop on Oncology Initiatives |
| Year(s) Of Engagement Activity | 2019 |
| Description | NIHR Manchester Biomedical Research Centre- Health Innovation Manchester Industry Advisory Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Discussions took place on topics such as: Biomarkers in the Manchester BRC; how Biomarker offering be promoted to industry; imaging capabilities across Manchester and how to improve the industry experience of navigating the Manchester landscape |
| Year(s) Of Engagement Activity | 2019 |
| Description | School visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | 14 children visited from a local primary school and participated in child-friendly protein science experiments related to our research, supervised by teachers and lab technicians. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Scouts visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Third sector organisations |
| Results and Impact | 30 Scouts aged 10-11 attended an evening visit to the Stoller Biomarker Discovery Centre, including different protein science experiment stations related to our research. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Stoller Launch and Symposium 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A two day symposium with visiting speakers from across the UK and international precision medicine and proteomics communities. Attendees ranged from postdoctoral students, academics and industry representatives working in the field. There was also a formal launch event attended by our collaborative partners from SCIEX and the Danaher Corporation, and a ribbon cutting ceremony with representatives from the Stoller Charitable Trust who have provided funding to the Stoller Centre. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Stratified Medicine Annual Consortium Meeting, Bristol, UK |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Annual consortium meeting which included discussions on progress of the project and presentation of results obtained at the Stoller Biomarker Discovery Centre. This positively increases the Stoller Biomarker Discovery Centre's reputation and level of respect both nationally and internationally. |
| Year(s) Of Engagement Activity | 2020 |
| Description | The Times, supplement called Future North |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | The Times (the supplement went into all copies of The Times in Yorkshire, North West and North East of England); a summary about importance of the Stoller Biomarker Discovery Centre in the biomarker discovery, validation and verification. |
| Year(s) Of Engagement Activity | 2019 |
| Description | UK Biobank Enhancement Working Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Development of a new multiomics approach on the UK Biobank cohort. |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | UK Biobank Enhancement Working Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Development of a new multiomics approach on the UK Biobank cohort and potential of imaging enhancements |
| Year(s) Of Engagement Activity | 2019 |
| Description | UK Biobank International Scientific Advisory Board Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Multiple discussions took place during the UK Biobank International Scientific Advisory Board Meeting including dissemination of results and discussions on how to take these forward. |
| Year(s) Of Engagement Activity | 2019 |
| Description | UK Biobank's COO and Director of Operations visited Stoller Biomarker Discovery Centre |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | UK Biobank's COO Mark Effingham and Director of Operations Simon Sheard visited Stoller Biomarker Centre on the 21st of November 2018 to see the facility and to discuss future collaboration with Prof. Tony Whetton. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Visit by the Medical Research Council |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Supporters |
| Results and Impact | A visit by approximately 20 MRC members, the President and Vice-Chancellor of The University of Manchester and the Dean of Faculty of Biology, Medicine and Health. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Visit from the Deputy Prime Minister from Singapore |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Visit from the Deputy Prime Minister and Manchester Alumni from Singapore on the 26th of March 2018. |
| Year(s) Of Engagement Activity | 2018 |